Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order
Executive Summary
A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business